Generic name:infliximab-abda (intravenous route) [ in-FLIX-i-mab-- abda ]
Drug class:TNF alfa inhibitors
Medically reviewed by Drugs.com. Last updated on Mar 16, 2022.
Increased risk of serious infections leading to hospitalization or death, including TB, bacterial sepsis, invasive fungal infections (such as histoplasmosis) and infections due to other opportunistic pathogens. Discontinue infliximab-abda if a patient develops a serious infection. Perform test for latent TB; if positive, start treatment for TB prior to starting infliximab-abda. Monitor all patients for active TB during treatment, even if initial latent TB test is negative. Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab. Postmarketing cases of fatal hepatosplenic T-cell lymphoma (HSTCL) have been reported in patients treated with TNF blockers including infliximab products. Almost all had received azathioprine or 6-mercaptopurine concomitantly with a TNF-blocker at or prior to diagnosis. The majority of reported cases have occurred in patients with Crohn’s disease or ulcerative colitis, most of whom were adolescent or young adult males .
Commonly used brand name(s)
In the U.S.
- Renflexis
Available Dosage Forms:
- Powder for Solution
Therapeutic Class: Immunological Agent
Pharmacologic Class: Infliximab
Uses for Renflexis
Infliximab-abda injection is used in adults to treat Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and chronic severe plaque psoriasis. It is used in children to treat Crohn's disease and ulcerative colitis. Infliximab-abda injection is a monoclonal antibody that works to enhance and improve the immune system.
This medicine is available only with your doctor's prescription.
Before using Renflexis
In deciding to use a medicine, the..
